Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
grade B 32.84 -0.42% -0.14
XNCR closed down 0.42 percent on Friday, May 24, 2019, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
2 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical XNCR trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Down 3 Days in a Row Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -0.42%
Outside Day Range Expansion -0.42%
20 DMA Support Bullish -4.34%
180 Bullish Setup Bullish Swing Setup -4.34%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.34%
Outside Day Range Expansion -4.34%

Older signals for XNCR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
Basic chart:

Profile
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Immune System Autoimmune Diseases Monoclonal Antibodies Rheumatoid Arthritis Antibody Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement
Is XNCR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
May 23 Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
May 10 Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT
May 10 Xencor up 5% on Q1 beat
May 10 Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2019 Results - Earnings Call Transcript
May 10 Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript
May 9 Xencor: 1Q Earnings Snapshot
May 9 Xencor beats by $1.79, beats on revenue
May 9 Xencor Reports First Quarter 2019 Financial Results
May 6 Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
May 2 Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
See more XNCR news...
Indicators
Indicator Value
52 Week High 48.38
52 Week Low 27.75
Average Volume 210,193
200-Day Moving Average 35.7795
50-Day Moving Average 32.1802
20-Day Moving Average 32.915
10-Day Moving Average 33.595
Average True Range 1.5605
ADX 14.41
+DI 21.1853
-DI 18.5429
Chandelier Exit (Long, 3 ATRs ) 32.2785
Chandelier Exit (Short, 3 ATRs ) 34.2815
Upper Bollinger Band 35.7321
Lower Bollinger Band 30.0979
Percent B (%b) 0.49
BandWidth 17.117424
MACD Line 0.4082
MACD Signal Line 0.489
MACD Histogram -0.0808
Fundamentals Value
Market Cap 1.54 Billion
Num Shares 46.9 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -37.75
Price-to-Sales 29.06
Price-to-Book 3.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.00
Resistance 3 (R3) 34.06 33.73 33.81
Resistance 2 (R2) 33.73 33.43 33.70 33.74
Resistance 1 (R1) 33.28 33.25 33.12 33.23 33.68
Pivot Point 32.95 32.95 32.87 32.92 32.95
Support 1 (S1) 32.51 32.66 32.34 32.45 32.00
Support 2 (S2) 32.18 32.47 32.15 31.94
Support 3 (S3) 31.73 32.18 31.87
Support 4 (S4) 31.68